Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.

PloS one - 1 Jan 2015

Wang Shuo-Yu, Wei Yau-Huei, Shieh Dar-Bin, Lin Li-Ling, Cheng Shih-Ping, Wang Pei-Wen, Chuang Jiin-Haur

Abstract excerpt

Tumor cells display a shift in energy metabolism from oxidative phosphorylation to aerobic glycolysis. A subset of papillary thyroid carcinoma (PTC) is refractory to surgery and radioactive iodine ablation. Doxorubicin and sorafenib are the drugs of choice for treating advanced thyroid cancer but both induce adverse effects. In this study, we assessed the anti-cancer activity of 2-deoxy-d-glucose (2-DG) alone and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxyglucose
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glycolysis

Share to Lactic Acid

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Share to Thyroid Gland

Source

Open in PubMed Open full text

Identifiers

PMID: 26134286
DOI: 10.1371/journal.pone.0130959
PMCID: PMC4489888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.PMID 26134286Read ↗

Targeting the Warburg Effect in Anaplastic and Poorly Differentiated Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic OpportunitiesSemantic proximity Read ↗

Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment.Semantic proximity Read ↗

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.Semantic proximity Read ↗

Convergent Mechanistic Pathways Driving the Anaplastic Phenotype in Thyroid Cancer.Semantic proximity Read ↗

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancerSemantic proximity Read ↗

BRAFV600E/p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer.Semantic proximity Read ↗

Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype.Semantic proximity Read ↗

SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathwaysSemantic proximity Read ↗

Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid CancerSemantic proximity Read ↗

Autophagy sustains mitochondrial respiration and determines resistance to BRAF V600E inhibition in thyroid carcinoma cellsSemantic proximity Read ↗

The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.